GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (FRA:ITH) » Definitions » Cyclically Adjusted PB Ratio

Nektar Therapeutics (FRA:ITH) Cyclically Adjusted PB Ratio : 0.40 (As of Jun. 06, 2024)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-06), Nektar Therapeutics's current share price is €1.268. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €3.21. Nektar Therapeutics's Cyclically Adjusted PB Ratio for today is 0.40.

The historical rank and industry rank for Nektar Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:ITH' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.12   Med: 7.26   Max: 130.53
Current: 0.37

During the past years, Nektar Therapeutics's highest Cyclically Adjusted PB Ratio was 130.53. The lowest was 0.12. And the median was 7.26.

FRA:ITH's Cyclically Adjusted PB Ratio is ranked better than
77.16% of 661 companies
in the Biotechnology industry
Industry Median: 1.75 vs FRA:ITH: 0.37

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was €0.635. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €3.21 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted PB Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.93 6.19 4.28 0.65 0.15

Nektar Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.16 0.16 0.15 0.24

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.



Nektar Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nektar Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.268/3.21
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.635/131.7762*131.7762
=0.635

Current CPI (Mar. 2024) = 131.7762.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 -0.204 100.560 -0.267
201409 0.286 100.428 0.375
201412 0.225 99.070 0.299
201503 0.543 99.621 0.718
201506 0.237 100.684 0.310
201509 0.261 100.392 0.343
201512 0.044 99.792 0.058
201603 -0.002 100.470 -0.003
201606 -0.256 101.688 -0.332
201609 -0.439 101.861 -0.568
201612 0.545 101.863 0.705
201703 0.270 102.862 0.346
201706 0.019 103.349 0.024
201709 0.450 104.136 0.569
201712 0.465 104.011 0.589
201803 0.291 105.290 0.364
201806 9.237 106.317 11.449
201809 8.865 106.507 10.968
201812 8.700 105.998 10.816
201903 8.298 107.251 10.196
201906 7.876 108.070 9.604
201909 7.690 108.329 9.354
201912 7.166 108.420 8.710
202003 6.596 108.902 7.981
202006 6.239 108.767 7.559
202009 5.542 109.815 6.650
202012 4.917 109.897 5.896
202103 4.583 111.754 5.404
202106 4.087 114.631 4.698
202109 3.692 115.734 4.204
202112 3.242 117.630 3.632
202203 2.963 121.301 3.219
202206 2.316 125.017 2.441
202209 2.215 125.227 2.331
202212 1.836 125.222 1.932
202303 1.189 127.348 1.230
202306 0.956 128.729 0.979
202309 0.783 129.860 0.795
202312 0.628 129.419 0.639
202403 0.635 131.776 0.635

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (FRA:ITH) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nektar Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics (FRA:ITH) Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, the company is focused on activating the immune system's natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.

Nektar Therapeutics (FRA:ITH) Headlines

No Headlines